GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting weight loss.
The observational study (COM2-0186-22), presented during the European Congress on Obesity (ECO) taking place in Malaga, Spain between 11-14 May and published in the journal eClinicalMedicine, investigated first-generation GLP-1RAs Victoza (liraglutide) and Byetta (exenatide).
The study found that GLP1-RAs had a direct effect on reducing obesity-related cancer beyond weight loss, with a 41% lower relative risk compared to bariatric surgery.
Researchers analysed electronic health record data and over a median follow-up of 7.5 years, 298 patients were diagnosed with obesity-related cancer. Of these cases, 150 were from 3,178 surgery patients (5.76 cases per 1,000 person-years) compared with 148 cases from 3,178 patients taking GLP-1RAs (5.64 cases per 1,000 person-years). This comes as bariatric surgery in weight reduction is already known to reduce cancer risk.
The most common cancer was postmenopausal breast cancer (26%), followed by colorectal cancer (16%), and cancer of the uterus (15%).
To assess the comparative effect beyond the extent of weight loss (which mediates the reduction in cancer risk following treatment), the researchers further adjusted the analysis for the percentage of maximal BMI change during follow-up.
Co-lead author Dr Yael Wolff Sagy from Clalit Health Services, Tel-Aviv, Israel, said: 'Our study found a similar incidence of obesity-related cancer among patients treated with first-generation GLP-1RAs and with bariatric surgery over an average of 8 years follow-up, despite the relative advantage of surgery in maximising weight loss. But accounting for this advantage revealed the direct effect of GLP-1RAs beyond weight loss to be 41% more effective at preventing obesity-related cancer.'
Of the 6,356 study participants, 3,884 (61.1%) were females. At baseline, the mean age was 52.3 years, and the mean BMI was 41.5kg/m².
Both obesity and diabetes are linked with an increased risk for many types of cancer, referred to as obesity-related cancer, including colorectal cancer, corpus uteri cancer, meningioma and ovarian cancer, as well as multiple myeloma.
Investigators are now calling for randomised trials and larger prospective studies to confirm the anti-cancer effects of GLP-1RAs noted in the observational study and explore the underlying mechanisms.
GLP-1RAs are also being investigated in other indications beyond obesity and type 2 diabetes, including Alzheimer's disease, addictive disorders and psychiatric disorders.
GLP-1RAs have grown massively in recent years following the release of Novo Nordisk's semaglutide, marketed as Ozempic in type 2 diabetes and Wegovy in obesity, and Eli Lilly's tirzepatide, marketed as Mounjaro in type 2 diabetes and Zepbound in obesity.
GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033. Research also predicts Novo Nordisk and Eli Lilly will dominate the market, collectively capturing 94% of the total 2030 GLP-1RA sales.
GlobalData is the parent company of Clinical Trials Arena.
"GLP-1RAs show anti-cancer benefits beyond weight loss" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Women on blockbuster weight loss drugs warned to use effective contraception
Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.
Newsweek
an hour ago
- Newsweek
Women on Weight-Loss Drugs Warned of Surprise 'Ozempic Babies'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Women taking popular weight-loss drugs have been urged to use effective contraception while taking the medication amid reports of a so-called "Ozempic babies" phenomenon. The advice was issued by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), an executive agency of the Department of Health and Social Care, on Thursday. Newsweek reached out to the U.S. Department of Health and Human Services for comment via email. Why It Matters Demand for weight-loss drugs, including GLP-1 medications such as Ozempic, Wegovy, and Mounjaro, has surged in the United States. In May 2024, a KFF Health Tracking Poll found that approximately 6 percent of American adults—about 15 million people—were using GLP-1 agonists such as Ozempic, either for diabetes treatment or weight loss. Some experts have cautioned that women should use effective contraception while taking these medications amid reports that they may be linked to an increase in unexpected pregnancies, The Guardian reported last May. A person injects Ozempic into their abdomen on October 10, 2024, in Sydney, Australia. A person injects Ozempic into their abdomen on October 10, 2024, in Sydney, Australia. Steve Christo - Corbis/Corbis/Getty Images What To Know The MHRA issued its alert after receiving 40 reports related to pregnancies while using "GLP-1 medicines," which are known by the brand names Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza. Ozempic and Wegovy contain semaglutide, which mimics the GLP-1 hormone to increase insulin, slow digestion, and suppress appetite. Mounjaro contains tirzepatide, which acts on an additional hormone related to blood sugar and appetite control. The MHRA warned that Mounjaro may reduce the effectiveness of oral contraceptives in people who are overweight. It received 26 pregnancy-related reports for Mounjaro alone. "Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception," the agency said. "This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase." Hundreds of women have shared personal accounts of unplanned pregnancies while using these medications in online groups, including the Facebook group "I got pregnant on Ozempic." "My ozempic baby...I see so many posts about ozempic and asking for "stories or side effects," but I never see anyone warning about pregnancy... lol," one woman shared on Facebook. "If you don't know, I got pregnant on ozempic and so many other women have too..I was on ozempic for 6 weeks & found out I was pregnant. I was so scared, google had me frightened I would miscarry because of the ozempic. I then came across a group called 'I got pregnant on ozempic'. I started reading all of these stories about women fighting infertility and getting pregnant on ozempic." The Food and Drug Administration has not yet issued similar advisories in the United States. What People Are Saying MHRA Chief Safety Officer Dr. Alison Cave said: "Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight, and have not been assessed to be safe when used in this way. "Our guidance offers patients a 'one stop shop' for our up-to-date advice on how to use these powerful medicines safely. "This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process." Dr. Ilana Ressler, a reproductive endocrinologist at Illume Fertility, told Interesting Engineering on May 22: "There is this phenomenon of Ozempic what I think what's happening is women who may not have been ovulating before with the improvements that the medication is bringing on, that might be helping them to ovulate more regularly and they might be more likely to conceive while on the medication than not—so it is recommended to avoid pregnancy while taking the medication." Dr. Zuri A. Murrell, in a video on X last year: "There is nothing magical about the medicine that's in Ozempic that helps you get pregnant. But what it does is that a lot of times, when people can't, it's because of a hormone weight imbalance. "And so, when you lose weight, and sometimes when you lose weight rapidly, the hormones and the new you aren't in concert. Or they really are in concert, and guess what can happen, pregnancy. "So, it's not the Ozempic itself, it is actually the balancing out of your hormones. That means that you've lost fat, and that the body actually for you is working like it should. So just remember, Ozempic is not something that somebody takes and 'I'm pregnant.' What it does do is cause your body and hormone level to be more in sync and more likely that you can." What Happens Next It remains unclear whether the FDA will follow the MHRA's lead in issuing similar warnings or guidance on contraception.
Yahoo
2 hours ago
- Yahoo
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck MRK is interested in acquiring the company. Per the article, Merck had submitted a non-binding offer for MoonLake earlier this year in a deal valued at more than $3 billion. Though this offer was rejected, the FT stated that the talks could be revived and other suitors may express interest in acquiring MLTX. Both Merck and MoonLake have declined to comment on the rumor. Swiss-based MoonLake Immunotherapeutics is a clinical-stage company developing its lead pipeline asset, sonelokimab, for the treatment of inflammatory diseases. The drug is a novel nanobody therapy being developed in late-stage studies for hidradenitis suppurativa (HS) and psoriatic arthritis (PsA) indications. Topline data from the HS study is expected around September 2025. MoonLake is also developing sonelokimab for other indications in dermatology and rheumatology, including palmo-plantar pustulosis (PPP) and axial spondyloarthritis (axSpA). Year to date, the stock has lost 10% compared with the industry's 4% decline. Image Source: Zacks Investment Research The idea behind the deal is clear — Merck aims to diversify its current revenue base, which has become highly dependent on Keytruda. In 2024, the company generated nearly 46% of its total revenues from the drug's sales. With concerns over Keytruda's potential loss of exclusivity (LOE) after 2028, MRK remains under pressure from the investor community to pursue deals for new drugs that could help reduce its dependence on a single product for growth. In the past year, Merck has been tapping Chinese biotechs for licensing deals. Toward the end of last year, the company struck multi-billion-dollar deals with Hansoh Pharma, LaNova Medicines and Hengrui Pharma. While the Hansoh deal added the investigational oral GLP-1 receptor agonist HS-10535 to Merck's pipeline, the LaNova deal added the experimental bispecific VEGF/PD-1 antibody LM-299. With the Hengrui Pharma deal, Merck acquired rights to an investigational oral small-molecule lipoprotein(a) inhibitor, HRS-5346. While broader macroeconomic concerns — including Trump-era tariffs and leadership shifts at the FDA — have weighed on deal-making in 2025, Big Pharma continues to pursue strategic assets in key growth areas. This week, Sanofi SNY announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on blockbuster drug Dupixent. Through this transaction, Sanofi intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Sanofi expects to close this deal in the third quarter of 2025. In parallel, Bristol Myers Squibb BMY signed a co-development and commercialization agreement with BioNTech for BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF. The deal gives Bristol Myers access to a promising oncology candidate across multiple tumor types, aligning with its strategy to offset revenue declines from legacy brands. These transactions highlight the industry's ongoing interest in targeted immunology and oncology platforms — the same areas MoonLake's sonelokimab is exploring. Merck's rumored pursuit of MoonLake fits this trend, signaling that small biotechs with promising assets remain top M&A targets for Big Pharma. MoonLake Immunotherapeutics price | MoonLake Immunotherapeutics Quote MoonLake currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report MoonLake Immunotherapeutics (MLTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
